NVIDIA Co. (NVDA) Given Consensus Rating of “Buy” by Brokerages

NVIDIA Co. (NASDAQ:NVDA) has been assigned an average rating of “Buy” from the thirty-eight brokerages that are currently covering the company, …

NVIDIA logoNVIDIA Co. (NASDAQ:NVDA) has been assigned an average rating of “Buy” from the thirty-eight brokerages that are currently covering the company, Marketbeat reports. Four analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and twenty-six have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $252.17.

Several brokerages recently issued reports on NVDA. ValuEngine cut NVIDIA from a “hold” rating to a “sell” rating in a research report on Monday, November 12th. Royal Bank of Canada dropped their price target on NVIDIA from $230.00 to $200.00 and set an “outperform” rating on the stock in a research report on Thursday. Raymond James lowered their price objective on NVIDIA from $300.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 16th. Deutsche Bank lowered their price objective on NVIDIA from $260.00 to $190.00 and set a “hold” rating on the stock in a report on Friday, November 16th. Finally, B. Riley reaffirmed a “neutral” rating and issued a $190.00 price objective (down previously from $240.00) on shares of NVIDIA in a report on Friday, November 16th.

In other news, EVP Ajay K. Puri sold 90,831 shares of the business’s stock in a transaction that occurred on Tuesday, October 2nd. The stock was sold at an average price of $289.35, for a total transaction of $26,281,949.85. Following the sale, the executive vice president now owns 184,001 shares of the company’s stock, valued at approximately $53,240,689.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Colette Kress sold 889 shares of the business’s stock in a transaction that occurred on Friday, December 14th. The stock was sold at an average price of $147.91, for a total value of $131,491.99. Following the sale, the chief financial officer now directly owns 259,912 shares in the company, valued at approximately $38,443,583.92. The disclosure for this sale can be found here. 4.70% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the company. Boston Family Office LLC raised its position in shares of NVIDIA by 141.7% during the 3rd quarter. Boston Family Office LLC now owns 2,175 shares of the computer hardware maker’s stock worth $611,000 after purchasing an additional 1,275 shares during the last quarter. Whittier Trust Co. raised its position in shares of NVIDIA by 18.3% during the 3rd quarter. Whittier Trust Co. now owns 29,872 shares of the computer hardware maker’s stock worth $8,394,000 after purchasing an additional 4,616 shares during the last quarter. Chicago Equity Partners LLC raised its position in shares of NVIDIA by 1.1% during the 3rd quarter. Chicago Equity Partners LLC now owns 31,020 shares of the computer hardware maker’s stock worth $8,717,000 after purchasing an additional 350 shares during the last quarter. OppenheimerFunds Inc. raised its position in shares of NVIDIA by 8,302.4% during the 2nd quarter. OppenheimerFunds Inc. now owns 311,478 shares of the computer hardware maker’s stock worth $73,789,000 after purchasing an additional 307,771 shares during the last quarter. Finally, Advisor Partners LLC raised its position in shares of NVIDIA by 5.0% during the 3rd quarter. Advisor Partners LLC now owns 16,269 shares of the computer hardware maker’s stock worth $4,572,000 after purchasing an additional 779 shares during the last quarter. 67.48% of the stock is currently owned by institutional investors and hedge funds.

NVDA stock traded up $2.48 during trading on Friday, hitting $133.65. The company had a trading volume of 15,702,274 shares, compared to its average volume of 13,710,813. The stock has a market capitalization of $81.19 billion, a PE ratio of 28.62, a price-to-earnings-growth ratio of 1.93 and a beta of 1.97. NVIDIA has a 1-year low of $124.46 and a 1-year high of $292.76. The company has a quick ratio of 6.20, a current ratio of 7.08 and a debt-to-equity ratio of 0.21.

NVIDIA (NASDAQ:NVDA) last issued its quarterly earnings results on Thursday, November 15th. The computer hardware maker reported $1.67 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.73 by ($0.06). The company had revenue of $3.18 billion during the quarter, compared to analyst estimates of $3.24 billion. NVIDIA had a net margin of 37.78% and a return on equity of 51.60%. Analysts expect that NVIDIA will post 6.45 earnings per share for the current fiscal year.

About NVIDIA

NVIDIA Corporation operates as a visual computing company worldwide. It operates through two segments, GPU and Tegra Processor. The GPU segment offers processors, which include GeForce for PC gaming and mainstream PCs; GeForce NOW for cloud-based game-streaming service; Quadro for design professionals working in computer-aided design, video editing, special effects, and other creative applications; Tesla for AI utilizing deep learning, accelerated computing, and general purpose computing; GRID provides power of NVIDIA graphics through the cloud and datacenters; DGX for AI scientists, researchers, and developers; and cryptocurrency-specific graphics processing units.

Further Reading: Why does a company issue an IPO?

Analyst Recommendations for NVIDIA (NASDAQ:NVDA)

Receive News & Ratings for NVIDIA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NVIDIA and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Nvidia (NVDA) Share Price Declined While Mitsubishi Ufj Securities Holdings Company Has …

Emerald Mutual Fund Advisers Trust increased its stake in Neogenomics Inc (NEO) by 250.77% based on its latest 2018Q3 regulatory filing with the …

NVIDIA Corporation (NASDAQ:NVDA) Logo

Emerald Mutual Fund Advisers Trust increased its stake in Neogenomics Inc (NEO) by 250.77% based on its latest 2018Q3 regulatory filing with the SEC. Emerald Mutual Fund Advisers Trust bought 1.11 million shares as the company’s stock rose 4.81% while stock markets declined. The institutional investor held 1.56M shares of the health care company at the end of 2018Q3, valued at $23.90 million, up from 443,806 at the end of the previous reported quarter. Emerald Mutual Fund Advisers Trust who had been investing in Neogenomics Inc for a number of months, seems to be bullish on the $1.49B market cap company. The stock increased 2.06% or $0.32 during the last trading session, reaching $15.82. About 1.30M shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has risen 52.35% since January 20, 2018 and is uptrending. It has outperformed by 52.35% the S&P500. Some Historical NEO News: 20/04/2018 – DJ NeoGenomics Inc, Inst Holders, 1Q 2018 (NEO); 20/03/2018 – NEOGENOMICS INC NEO.O SAYS SHARON VIRAG APPOINTED CFO; 20/03/2018 – NeoGenomics Names George Cardoza Pres of Pharma Services Division, Sharon Virag CFO; 01/05/2018 – NeoGenomics Backs 2018 Adj EPS 15c-Adj EPS 20c; 25/05/2018 – NeoGenomics to Participate In Two Upcoming Investor Conferences; 02/04/2018 – NeoGenomics Closes Below 50-Day Moving Average: Technicals; 01/05/2018 – NeoGenomics Backs 2018 EBIT $39M-EBIT $43M; 20/03/2018 – NEOGENOMICS INC – APPOINTMENT OF GEORGE CARDOZA AS PRESIDENT OF PHARMA SERVICES DIVISION; 01/05/2018 – NeoGenomics 1Q Adj EPS 4c; 01/05/2018 – NeoGenomics Backs 2018 Loss/Shr 13c-Loss 8c

Mitsubishi Ufj Securities Holdings Company increased its stake in Nvidia Corp (NVDA) by 156.33% based on its latest 2018Q3 regulatory filing with the SEC. Mitsubishi Ufj Securities Holdings Company bought 3,580 shares as the company’s stock declined 44.72% with the market. The institutional investor held 5,870 shares of the semiconductors company at the end of 2018Q3, valued at $1.65M, up from 2,290 at the end of the previous reported quarter. Mitsubishi Ufj Securities Holdings Company who had been investing in Nvidia Corp for a number of months, seems to be bullish on the $95.73B market cap company. The stock increased 3.43% or $5.21 during the last trading session, reaching $156.93. About 16.28 million shares traded. NVIDIA Corporation (NASDAQ:NVDA) has declined 20.90% since January 20, 2018 and is downtrending. It has underperformed by 20.90% the S&P500. Some Historical NVDA News: 27/03/2018 – NVDA, GOOG, INTC: BREAKING: NVIDIA Temporarily Suspends Self Driving Testing Across Globe Following Uber Fatality $NVDA – ! $NVDA $GOOG $INTC; 28/03/2018 – Chipmaker Nvidia’s CEO says Uber does not use its self-driving processing solution; 10/05/2018 – Nvidia 1Q EPS $1.98; 30/04/2018 – Fidelity Select Electronics Adds NXP Semi, Buys More Nvidia; 27/03/2018 – NVIDIA NVDA.O LAUNCHES DRIVE CONSTELLATION, CLOUD-BASED SELF-DRIVING CAR SIMULATOR; 27/03/2018 – Nvidia reportedly suspends self-driving tests globally; 20/03/2018 – Nvidia Corp: Big Blue Touts Partnership with NVIDIA at IBM Think Confab -; 27/03/2018 – NVIDIA Boosts World’s Leading Deep Learning Computing Platform, Bringing 10x Performance Gain in Six Months; 10/05/2018 – Nvidia Sees 2Q Rev $3.10B, Plus or Minus 2; 27/03/2018 – NVIDIA: MACHINE-DRIVEN CARS WILL BE SAFER THAN HUMAN DRIVERS

Since September 4, 2018, it had 0 insider purchases, and 6 selling transactions for $33.34 million activity. 11,576 NVIDIA Corporation (NASDAQ:NVDA) shares with value of $3.08 million were sold by Kress Colette. Another trade for 90,831 shares valued at $26.28M was sold by Puri Ajay K. Shoquist Debora also sold $858,685 worth of NVIDIA Corporation (NASDAQ:NVDA) shares.

More notable recent NVIDIA Corporation (NASDAQ:NVDA) news were published by: Cnbc.com which released: “Nvidia’s 54 percent plunge this quarter makes it the biggest loser in S&P 500 – CNBC” on December 21, 2018, also Seekingalpha.com with their article: “This Is Why Nvidia’s Stock May Fall Further – Seeking Alpha” published on December 27, 2018, Nasdaq.com published: “Technology Sector Update for 01/07/2019: TIVO, AAPL, QTRH, NVDA, MSFT, IBM, CSCO, GOOG – Nasdaq” on January 07, 2019. More interesting news about NVIDIA Corporation (NASDAQ:NVDA) were released by: Nasdaq.com and their article: “NVIDIA in Legal Tussle as Investors File Class-Action Lawsuit – Nasdaq” published on January 03, 2019 as well as Nasdaq.com‘s news article titled: “3 Top Crypto Stocks for 2019 – Nasdaq” with publication date: December 30, 2018.

Investors sentiment decreased to 1.36 in Q3 2018. Its down 0.24, from 1.6 in 2018Q2. It dived, as 64 investors sold NVDA shares while 312 reduced holdings. 130 funds opened positions while 380 raised stakes. 371.72 million shares or 2.91% more from 361.20 million shares in 2018Q2 were reported. The Washington-based Fisher Asset Llc has invested 0.05% in NVIDIA Corporation (NASDAQ:NVDA). Zweig holds 0.23% or 10,000 shares. Advsr Asset Management stated it has 25,965 shares. The Texas-based Frontier Investment Management has invested 0.5% in NVIDIA Corporation (NASDAQ:NVDA). Moreover, Cornerstone Advisors has 0.3% invested in NVIDIA Corporation (NASDAQ:NVDA) for 14,700 shares. World Asset Mngmt accumulated 40,953 shares. Institute For Wealth Lc reported 23,307 shares stake. Nomura reported 0.46% stake. Moreover, Renaissance Tech Limited Liability Company has 0.6% invested in NVIDIA Corporation (NASDAQ:NVDA). Schroder Grp accumulated 386,621 shares or 0.19% of the stock. Provise Management Gp Ltd Liability Com owns 4,591 shares or 0.17% of their US portfolio. Macroview Management Lc holds 0.01% of its portfolio in NVIDIA Corporation (NASDAQ:NVDA) for 10 shares. 9,582 are owned by Moors And Cabot. Winfield Assoc Inc holds 0.1% of its portfolio in NVIDIA Corporation (NASDAQ:NVDA) for 720 shares. 2,300 were accumulated by New Jersey Better Educational Savings Trust.

Among 49 analysts covering Nvidia Corporation (NASDAQ:NVDA), 34 have Buy rating, 3 Sell and 12 Hold. Therefore 69% are positive. Nvidia Corporation had 232 analyst reports since August 3, 2015 according to SRatingsIntel. M Partners maintained NVIDIA Corporation (NASDAQ:NVDA) on Tuesday, November 22 with “Buy” rating. The firm has “Hold” rating by Stifel Nicolaus given on Sunday, September 24. The stock has “Underweight” rating by Pacific Crest on Tuesday, April 4. The stock has “Underweight” rating by Barclays Capital on Friday, August 12. Citigroup maintained the shares of NVDA in report on Friday, January 12 with “Buy” rating. On Friday, November 6 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. TH Capital upgraded the shares of NVDA in report on Friday, August 7 to “Neutral” rating. The rating was maintained by Morgan Stanley with “Equal-Weight” on Friday, February 9. TH Capital reinitiated NVIDIA Corporation (NASDAQ:NVDA) on Monday, October 12 with “Neutral” rating. The firm has “Buy” rating by RBC Capital Markets given on Friday, November 24.

Emerald Mutual Fund Advisers Trust, which manages about $1.06 billion and $2.96B US Long portfolio, decreased its stake in Reata Pharmaceuticals Inc by 42,249 shares to 444,492 shares, valued at $36.34M in 2018Q3, according to the filing. It also reduced its holding in Extraction Oil & Gas by 662,965 shares in the quarter, leaving it with 642,868 shares, and cut its stake in Gtt Communications Inc (NYSE:GTT).

Among 15 analysts covering NeoGenomics (NASDAQ:NEO), 13 have Buy rating, 1 Sell and 1 Hold. Therefore 87% are positive. NeoGenomics had 23 analyst reports since September 3, 2015 according to SRatingsIntel. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Overweight” rating given on Thursday, December 15 by Cantor Fitzgerald. The firm has “Buy” rating by Roth Capital given on Wednesday, May 11. Stephens maintained NeoGenomics, Inc. (NASDAQ:NEO) rating on Tuesday, June 26. Stephens has “Buy” rating and $1500 target. William Blair maintained the shares of NEO in report on Sunday, September 6 with “Outperform” rating. The firm earned “Buy” rating on Thursday, September 3 by Roth Capital. The rating was reinitiated by TH Capital with “Buy” on Monday, October 26. The firm earned “Equal-Weight” rating on Wednesday, May 2 by First Analysis. Cantor Fitzgerald maintained the stock with “Buy” rating in Friday, May 26 report. Axiom Capital downgraded NeoGenomics, Inc. (NASDAQ:NEO) on Wednesday, November 16 to “Sell” rating. BTIG Research downgraded the stock to “Neutral” rating in Wednesday, July 27 report.

Since July 30, 2018, it had 1 insider purchase, and 8 sales for $208.58 million activity. 5,000 NeoGenomics, Inc. (NASDAQ:NEO) shares with value of $80,800 were sold by TETRAULT LYNN A.. $1.12M worth of NeoGenomics, Inc. (NASDAQ:NEO) shares were sold by Johnson Kevin C. SHOVLIN ROBERT J. sold $3.68M worth of stock. The insider JONES STEVEN C sold 203,500 shares worth $2.85 million. The insider BALLIET JENNIFER sold 68,333 shares worth $1.15 million.

NVIDIA Corporation (NASDAQ:NVDA) Institutional Positions Chart

Related Posts:

  • No Related Posts

First Hawaiian Bank Sells 160 Shares of Alteryx Inc (AYX)

First Hawaiian Bank lowered its stake in Alteryx Inc (NYSE:AYX) by 3.1% during the fourth quarter, according to the company in its most recent …

Alteryx logoFirst Hawaiian Bank lowered its stake in Alteryx Inc (NYSE:AYX) by 3.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,010 shares of the company’s stock after selling 160 shares during the period. First Hawaiian Bank’s holdings in Alteryx were worth $298,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in AYX. Capital World Investors increased its holdings in shares of Alteryx by 87.8% in the third quarter. Capital World Investors now owns 3,230,433 shares of the company’s stock valued at $184,813,000 after purchasing an additional 1,510,000 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Alteryx by 444.3% in the third quarter. Renaissance Technologies LLC now owns 894,298 shares of the company’s stock valued at $51,163,000 after purchasing an additional 730,000 shares during the period. Franklin Resources Inc. increased its holdings in shares of Alteryx by 644.7% in the third quarter. Franklin Resources Inc. now owns 773,719 shares of the company’s stock valued at $44,264,000 after purchasing an additional 669,819 shares during the period. BlackRock Inc. increased its holdings in shares of Alteryx by 47.8% in the second quarter. BlackRock Inc. now owns 2,027,578 shares of the company’s stock valued at $77,373,000 after purchasing an additional 655,701 shares during the period. Finally, Capital International Investors acquired a new position in shares of Alteryx in the third quarter valued at approximately $32,953,000. 53.99% of the stock is currently owned by institutional investors and hedge funds.

In related news, major shareholder Abdiel Capital Management, Llc purchased 90,000 shares of the business’s stock in a transaction dated Tuesday, October 30th. The stock was bought at an average cost of $47.40 per share, with a total value of $4,266,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kevin Rubin sold 8,500 shares of the business’s stock in a transaction on Monday, January 14th. The stock was sold at an average price of $67.46, for a total value of $573,410.00. The disclosure for this sale can be found here. Over the last three months, insiders bought 194,855 shares of company stock valued at $9,551,233 and sold 175,501 shares valued at $9,594,005. Insiders own 39.01% of the company’s stock.

AYX has been the topic of a number of recent research reports. Zacks Investment Research raised Alteryx from a “hold” rating to a “buy” rating and set a $65.00 target price on the stock in a report on Friday, November 9th. Citigroup set a $85.00 price target on Alteryx and gave the company a “buy” rating in a research note on Friday, November 9th. Bank of America lifted their price target on Alteryx from $54.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, November 9th. Needham & Company LLC lifted their price target on Alteryx from $65.00 to $74.00 and gave the company a “buy” rating in a research note on Thursday, November 8th. Finally, TheStreet upgraded Alteryx from a “d+” rating to a “c” rating in a research note on Thursday, November 8th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $66.92.

AYX opened at $73.52 on Friday. The company has a quick ratio of 2.64, a current ratio of 2.64 and a debt-to-equity ratio of 0.88. Alteryx Inc has a one year low of $24.46 and a one year high of $73.67.

Alteryx (NYSE:AYX) last posted its earnings results on Wednesday, November 7th. The company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.13. The company had revenue of $54.18 million for the quarter, compared to the consensus estimate of $49.79 million. Alteryx had a negative return on equity of 7.06% and a negative net margin of 6.72%. Alteryx’s quarterly revenue was up 58.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.02 earnings per share. Sell-side analysts expect that Alteryx Inc will post -0.3 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.fairfieldcurrent.com/news/2019/01/19/first-hawaiian-bank-sells-160-shares-of-alteryx-inc-ayx.html.

Alteryx Profile

Alteryx, Inc operates a self-service data analytics software platform that enables organizations to enhance business outcomes and the productivity of their business analysts. Its software platform includes Alteryx Designer for data preparation, blending, and analytics that could be deployable in the cloud and on premise; Alteryx Server, a secure and scalable server-based product for scheduling, sharing, and running analytic processes and applications in a Web-based environment; Alteryx Connect, a collaborative data exploration platform for discovering information assets and sharing recommendations across the enterprise; Alteryx Promote, an analytics model management product for data scientists and analytics teams to build, manage, monitor, and deploy predictive models to production; and Alteryx Analytics Gallery, a cloud-based collaboration offering that allows users to share workflows in a centralized repository.

Featured Story: Why is Cost of Capital Important?

Want to see what other hedge funds are holding AYX?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alteryx Inc (NYSE:AYX).

Institutional Ownership by Quarter for Alteryx (NYSE:AYX)

Receive News & Ratings for Alteryx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alteryx and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Envestnet Asset Management Inc. Has $208000 Holdings in HCA Healthcare Inc (NYSE:HCA)

Millennium Management LLC boosted its stake in shares of HCA Healthcare by 32.3% during the second quarter. Millennium Management LLC now …

HCA Healthcare logoEnvestnet Asset Management Inc. decreased its position in shares of HCA Healthcare Inc (NYSE:HCA) by 50.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,496 shares of the company’s stock after selling 1,525 shares during the quarter. Envestnet Asset Management Inc.’s holdings in HCA Healthcare were worth $208,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Panagora Asset Management Inc. boosted its stake in shares of HCA Healthcare by 44.0% during the third quarter. Panagora Asset Management Inc. now owns 36,733 shares of the company’s stock worth $5,110,000 after buying an additional 11,216 shares during the period. Millennium Management LLC boosted its stake in shares of HCA Healthcare by 32.3% during the second quarter. Millennium Management LLC now owns 1,698,536 shares of the company’s stock worth $174,270,000 after buying an additional 414,877 shares during the period. WINTON GROUP Ltd boosted its stake in shares of HCA Healthcare by 3,350.7% during the third quarter. WINTON GROUP Ltd now owns 205,078 shares of the company’s stock worth $28,530,000 after buying an additional 199,135 shares during the period. C WorldWide Group Holding A S boosted its stake in shares of HCA Healthcare by 16.6% during the third quarter. C WorldWide Group Holding A S now owns 92,727 shares of the company’s stock worth $12,900,000 after buying an additional 13,192 shares during the period. Finally, Aperio Group LLC boosted its stake in shares of HCA Healthcare by 7.5% during the third quarter. Aperio Group LLC now owns 224,614 shares of the company’s stock worth $31,248,000 after buying an additional 15,680 shares during the period. 69.74% of the stock is currently owned by institutional investors.

In related news, insider Michael S. Cuffe sold 5,196 shares of HCA Healthcare stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $136.52, for a total transaction of $709,357.92. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jane D. Englebright sold 5,081 shares of HCA Healthcare stock in a transaction on Friday, November 9th. The shares were sold at an average price of $141.90, for a total transaction of $720,993.90. Following the transaction, the senior vice president now owns 16,504 shares in the company, valued at approximately $2,341,917.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,763 shares of company stock worth $2,346,147. 2.80% of the stock is owned by company insiders.

HCA stock opened at $134.54 on Friday. The company has a market capitalization of $45.54 billion, a price-to-earnings ratio of 20.42, a PEG ratio of 1.07 and a beta of 0.69. HCA Healthcare Inc has a one year low of $90.06 and a one year high of $147.42.

HCA Healthcare (NYSE:HCA) last released its earnings results on Tuesday, October 30th. The company reported $2.16 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.93 by $0.23. The firm had revenue of $11.45 billion during the quarter, compared to analysts’ expectations of $11.29 billion. HCA Healthcare had a net margin of 6.82% and a negative return on equity of 73.71%. HCA Healthcare’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.13 EPS. As a group, equities analysts anticipate that HCA Healthcare Inc will post 9.35 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, December 28th. Shareholders of record on Monday, December 3rd were issued a $0.35 dividend. The ex-dividend date of this dividend was Friday, November 30th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.04%. HCA Healthcare’s dividend payout ratio (DPR) is presently 21.24%.

A number of equities research analysts recently commented on HCA shares. Zacks Investment Research downgraded shares of HCA Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, December 11th. Credit Suisse Group raised their price objective on shares of HCA Healthcare from $156.00 to $165.00 and gave the company an “outperform” rating in a research report on Thursday, November 1st. Stephens started coverage on shares of HCA Healthcare in a research report on Monday, January 14th. They issued an “overweight” rating and a $143.00 price objective for the company. Finally, Argus raised their price objective on shares of HCA Healthcare from $150.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, November 6th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eighteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $143.14.

WARNING: This piece was posted by Fairfield Current and is the property of of Fairfield Current. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.fairfieldcurrent.com/news/2019/01/19/hca-healthcare-inc-hca-shares-sold-by-envestnet-asset-management-inc.html.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.

See Also: How accurate is the Rule of 72?

Institutional Ownership by Quarter for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for HCA Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Envestnet Asset Management Inc. Invests $214000 in Boulder Growth & Income Fund Inc (NYSE:BIF)

Millennium Management LLC raised its holdings in Boulder Growth & Income Fund by 134.6% in the second quarter. Millennium Management LLC …

Boulder Growth & Income Fund logoEnvestnet Asset Management Inc. acquired a new position in shares of Boulder Growth & Income Fund Inc (NYSE:BIF) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 19,053 shares of the closed-end fund’s stock, valued at approximately $214,000.

A number of other institutional investors have also recently made changes to their positions in the business. MML Investors Services LLC boosted its position in shares of Boulder Growth & Income Fund by 2.1% in the third quarter. MML Investors Services LLC now owns 289,875 shares of the closed-end fund’s stock worth $3,250,000 after acquiring an additional 5,889 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Boulder Growth & Income Fund by 14.7% in the third quarter. Wells Fargo & Company MN now owns 460,476 shares of the closed-end fund’s stock valued at $5,162,000 after buying an additional 58,959 shares during the period. Flagship Harbor Advisors LLC raised its holdings in Boulder Growth & Income Fund by 14.5% in the second quarter. Flagship Harbor Advisors LLC now owns 187,719 shares of the closed-end fund’s stock valued at $1,929,000 after buying an additional 23,723 shares during the period. Millennium Management LLC raised its holdings in Boulder Growth & Income Fund by 134.6% in the second quarter. Millennium Management LLC now owns 59,560 shares of the closed-end fund’s stock valued at $612,000 after buying an additional 34,172 shares during the period. Finally, Wedbush Securities Inc. raised its holdings in Boulder Growth & Income Fund by 50.3% in the third quarter. Wedbush Securities Inc. now owns 64,634 shares of the closed-end fund’s stock valued at $725,000 after buying an additional 21,626 shares during the period. Institutional investors own 14.71% of the company’s stock.

Shares of BIF traded up $0.13 during mid-day trading on Friday, reaching $10.67. 122,513 shares of the stock traded hands, compared to its average volume of 222,509. Boulder Growth & Income Fund Inc has a 12-month low of $9.45 and a 12-month high of $11.84.

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 31st. Stockholders of record on Thursday, January 24th will be given a dividend of $0.102 per share. This represents a $0.41 dividend on an annualized basis and a dividend yield of 3.82%. The ex-dividend date is Wednesday, January 23rd.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Fairfield Current and is owned by of Fairfield Current. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.fairfieldcurrent.com/news/2019/01/19/19053-shares-in-boulder-growth-income-fund-inc-bif-purchased-by-envestnet-asset-management-inc.html.

Boulder Growth & Income Fund Profile

Boulder Growth & Income Fund, Inc is a closed-ended balanced mutual fund launched and managed by Boulder Investment Advisers, LLC It is co-managed by Stewart West Indies Trading Co Ltd. and Rocky Mountain Advisers, Llc. The fund invests in public equity and fixed income markets across the globe. It seeks to invest in securities of companies operating across diversified industries.

Featured Story: Investing strategies using the yield curve

Institutional Ownership by Quarter for Boulder Growth & Income Fund (NYSE:BIF)

Receive News & Ratings for Boulder Growth & Income Fund Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Boulder Growth & Income Fund and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts